The Manufacturers Life Insurance Company Has $122,000 Stake in Nkarta, Inc. (NASDAQ:NKTX)

The Manufacturers Life Insurance Company boosted its holdings in Nkarta, Inc. (NASDAQ:NKTX) by 92.9% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 20,710 shares of the company’s stock after buying an additional 9,975 shares during the period. The Manufacturers Life Insurance Company’s holdings in Nkarta were worth $122,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of the business. Susquehanna Fundamental Investments LLC bought a new position in shares of Nkarta in the 1st quarter worth $788,000. Vanguard Group Inc. raised its holdings in shares of Nkarta by 26.0% during the first quarter. Vanguard Group Inc. now owns 1,966,271 shares of the company’s stock worth $21,255,000 after acquiring an additional 405,753 shares during the period. Federated Hermes Inc. boosted its position in Nkarta by 28,478.7% during the 2nd quarter. Federated Hermes Inc. now owns 135,749 shares of the company’s stock worth $802,000 after acquiring an additional 135,274 shares during the last quarter. AQR Capital Management LLC bought a new position in shares of Nkarta during the 2nd quarter worth approximately $938,000. Finally, Cubist Systematic Strategies LLC acquired a new stake in shares of Nkarta in the second quarter valued at approximately $1,489,000. 80.54% of the stock is currently owned by institutional investors and hedge funds.

Nkarta Stock Up 6.5 %

Shares of Nkarta stock opened at $4.26 on Monday. The firm’s 50-day moving average price is $4.92 and its two-hundred day moving average price is $6.04. The company has a market capitalization of $210.51 million, a price-to-earnings ratio of -1.81 and a beta of 0.80. Nkarta, Inc. has a 12-month low of $1.81 and a 12-month high of $16.24.

Nkarta (NASDAQ:NKTX) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.49) by $0.15. On average, sell-side analysts expect that Nkarta, Inc. will post -1.92 earnings per share for the current year.

Wall Street Analysts Forecast Growth

NKTX has been the topic of a number of recent research reports. RODMAN&RENSHAW raised Nkarta to a “strong-buy” rating in a research report on Wednesday, October 9th. Rodman & Renshaw began coverage on Nkarta in a research report on Wednesday, October 9th. They set a “buy” rating and a $14.00 price target on the stock. HC Wainwright reduced their target price on shares of Nkarta from $23.00 to $22.00 and set a “buy” rating for the company in a report on Thursday, August 15th. Needham & Company LLC restated a “buy” rating and set a $13.00 price objective on shares of Nkarta in a report on Wednesday, August 14th. Finally, Raymond James upgraded Nkarta from an “outperform” rating to a “strong-buy” rating and set a $16.00 target price on the stock in a research note on Wednesday, August 14th. Five investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $17.50.

About Nkarta

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.